Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Immunogenic Reaction
"The immunogenic reaction affecting the systemic exposure and hence the toxicity profile, the NO(A)EL defined during the preclinical stage for PEG-IFNa-2B must be carefully interpreted and assessed given its importance in defining the Maximum Recommended Starting Dose(MRSD) in Phase I. In addition, the immunogenicity of PEG-IFNa-2B in non-human primates suggests a potential immunogenicity in humans that must be followed during the clinical trials.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society. OMICS Group also organizing 3000+ International Scientific Conferences and events yearly all over the world with the support of 1000+ Scientific associations worldwide.
Citation: Maraschiello C (2014) The Relevance of Immunogenicity in Preclinical development. J Bioanal Biomed 6: 001-004."
- Share this page
Last date updated on September, 2020